Novartis’ new CEO Vasant Narasimhan has indicated that the company might spin off its struggling U.S. generic pill business—and that is what it is preparing to do, sources are telling Reuters.
The news service today reported that Novartis is doing the legwork to auction off that piece of the Sandoz business, which might bring $1.6 billion from a competitor or private investors, Reuters said.
Outgoing CEO Joseph Jimenez and Narasimhan told analysts late last year that the Swiss drugmaker was looking at its options for the business in the face of rapid price erosion for generic pills in the U.S. They said a spinoff was one idea.
Narasimhan, in his first earnings call last month, said the company was looking at how to optimize the business in the face of ”significant pricing declines” and a poor climate that was unlikely to change anytime soon.
Executives have said they will concentrate U.S. efforts in complex generics and biosimilars.
By Eric Palmer
Source: Fierce Pharma
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
